Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0893 effects on glucagon-induced glycemia
NCT02012166Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of MK-0893 in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Merck & Co. Primary endpoint: Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min]. Started Jul 2005; status: completed.
02
Drugs
MK-0893
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02012166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012166.